-+ 0.00%
-+ 0.00%
-+ 0.00%

Soligenix halts Phase 3 FLASH2 HyBryte trial in CTCL for futility

PUBT·04/28/2026 11:30:59
Listen to the news
Soligenix halts Phase 3 FLASH2 HyBryte trial in CTCL for futility
  • Soligenix reported interim results from pivotal Phase 3 FLASH2 trial of HyBryte in cutaneous T-cell lymphoma.
  • Data Monitoring Committee recommended halting study for futility, citing lack of efficacy signal versus expectations from prior trial.
  • Management plans additional data review to assess whether any patient subgroups may still benefit.
  • Company flagged strategic review, citing about $5.9 million in cash.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604280730PR_NEWS_USPR_____PH43420) on April 28, 2026, and is solely responsible for the information contained therein.